Research programme: thorium-227 radiolabelled antibodies - Bayer/Progenics

Drug Profile

Research programme: thorium-227 radiolabelled antibodies - Bayer/Progenics

Alternative Names: 1095 - Bayer/Progenics; HER2 TTC; PSMA targeted therapeutics; PSMA TTC; PSMA-ADC; Trastuzumab-Th-227

Latest Information Update: 13 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Class Antibodies; Antineoplastics; Drug conjugates; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Gastric cancer; Lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Gastric cancer in Germany (Parenteral)
  • 01 Apr 2017 Preclinical trials in Lung cancer in Germany (Parenteral)
  • 01 Apr 2017 Preclinical trials in Ovarian cancer in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top